API SYNTHESIS INTERNATIONAL: Biocon’s Insulin Glargine gets approval in Japan

DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, this will not stop me, Only God and death can..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai), INDIA, worlddrugtracker, 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.8 Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributionn, सुकून उतना ही देना प्रभू, जितने से जिंदगी चल जाये।औकात बस इतनी देना,कि औरों का भला हो जाये।...........P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.

Thursday, 31 March 2016

Biocon’s Insulin Glargine gets approval in Japan

Avik Das | TNN | Mar 28, 2016, 02.52 PM IST
http://timesofindia.indiatimes.com/business/india-business/Biocons-Insulin-Glargine-gets-approval-in-Japan/articleshow/51583333.cms
BENGALURU: Biopharmaceutical company Biocon said it got approval from Japan's health ministry to sell its biosimilar Insulin Glargine in the country.
The product, which is a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine, is expected to be launched in Japan in the first quarter of 2017 with its commercial partner FUJIFILM Pharma Co. Ltd, Biocon said on Monday.
The move will help Biocon capture a significant share of the Japanese Glargine market, which is about $144 million and second largest market outside of North America & Europe.
"The Insulin Glargine approval in the highly regulated market like Japan, marks a huge credibility milestone for Biocon. We see this as a significant achievement in our journey of making global impact in diabetes management through our affordable biosimilar insulins," chairperson and managing director Kiran Mazumdar-Shaw said.

Kiran Mazumdar–Shaw

Biosimilars are biologic products, made inside living cells and has no clinical differences in terms of safety and effectiveness from the main product. They are however not considered duplicates, like generics, by regulators as it is impossible to manufacture exact copies of biotech drugs.

Biocon Limited

Type	Public company
Traded as	BSE: 532523 NSE: BIOCON
Industry	Biotechnology
Founded	1978
Founder	Kiran Mazumdar-Shaw
Headquarters	Bangalore, Karnataka, India
Key people	Kiran Mazumdar-Shaw, (Chairman & MD)
Products	Pharmaceuticals Enzymes
Revenue	₹22.41 billion (US$330 million) (2014–15)^[1]
Net income	₹3.61 billion (US$54 million) (2014–15)
Number of employees	5,585 (Mar 2011)^[1]
Subsidiaries	Syngene Clinigene
Website	www.biocon.com

//////Biocon, Insulin Glargine, approval, Japan